Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. (EVMN)
Company Research
Source: Business Wire
- Trial met primary efficacy endpoint at week 12- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo- 33% placebo-adjusted improvement in EASI at week 12- 23% of EVO301 patients achieved IGA 0/1 at week 12- Company to hold conference call and webcast at 8:30 a.m. ET today PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domain, achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis (AD). The 70-patient trial was designed to evaluate the safe
Show less
Read more
Impact Snapshot
Event Time:
EVMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVMN alerts
High impacting Evommune, Inc. news events
Weekly update
A roundup of the hottest topics
EVMN
News
- Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
- Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Evommune (NYSE:EVMN) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e)" rating on the stock.MarketBeat
- Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.MarketBeat
- Evommune (NYSE:EVMN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.MarketBeat
EVMN
Sec Filings
- 2/10/26 - Form 8-K
- 12/22/25 - Form 4
- 12/19/25 - Form 4
- EVMN's page on the SEC website